Abstract
In an attempt to elucidate the mechanism(s) of action of thalidomide, a reportedly antiangiogenic molecule recently tested in the treatment of relapsing malignant gliomas, we performed an in vitro study on the following parameters: (a) effect of thalidomide on proliferation of endothelial cells; (b) effect of thalidomide on expression of αvβ3 integrin on the surface of endothelial cells; (c) effect of thalidomide on the release by endothelial cells of MMP-2, IL-8 and TNF-α. The results show that thalidomide inhibits endothelial cell proliferation induced by bFGF and VEGF, more so if the cells are grown on vitronectin; moreover, treatment with thalidomide reduces the release of MMP-2 and IL-8 by endothelial cells, suggesting a further pathway for the antiangiogenic activity of drug. On the other hand, thalidomide does not modify expression of αvβ3 on endothelial cells.
Original language | English |
---|---|
Pages (from-to) | 193-201 |
Number of pages | 9 |
Journal | Journal of Neuro-Oncology |
Volume | 64 |
Issue number | 3 |
DOIs | |
Publication status | Published - Sep 2003 |
Keywords
- αvβ3
- Angiogenesis
- Endothelial proliferation
- IL-8
- Malignant glioma
- MMP-2
- Thalidomide
ASJC Scopus subject areas
- Cancer Research
- Clinical Neurology
- Oncology
- Neuroscience(all)